NCT02108002View on ClinicalTrials.gov

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 5, 2014

Primary Completion Date

September 12, 2018

Study Completion Date

September 12, 2018

Conditions
Von Hippel-Lindau Disease
Interventions
DRUG

Vorinostat

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT02108002 - Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) | Biotech Hunter | Biotech Hunter